We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
At a time drug companies are looking for new answers when it comes to developing new products and having a difficult time, the pharmaceutical industry may be on the verge of a different tact: turning to physcians and their advocacy organizations. Jeffrey Aronin, president and CEO of Ovation Pharmaceuticals Inc. tells the Chicago Tribune's Bruce Japsen about how his company has been getting some of its best ideas for drug development from doctors practicing in the field.
At a time drug companies are looking for new answers when it comes to developing new products and having a difficult time, the pharmaceutical industry may be on the verge of a different tact: turning to physcians and their advocacy organizations. Jeffrey Aronin, president and CEO of Ovation Pharmaceuticals Inc. tells the Chicago Tribune's Bruce Japsen about how his company has been getting some of its best ideas for drug development from doctors practicing in the field.
Stay current with the best on medical education
